Efficacy of niacin on phosphatic metabolism in patients with renal insufficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002221-31-DE

Enrollment

Registered

2005-07-05

Start date

2005-08-11

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exam the efficacy of niaspan in phosphate metabolism of patients with renal insufficiency, different exam for dialysis and predialysis patients

Interventions

Trade Name: Niaspan 375mg Product Name: Niaspan 375mg Product Code: 58895.00.00 Pharmaceutical Form: Prolonged-release tablet Trade Name: Niaspan 500mg Product Name: Niaspan 500mg Product Code: 58895

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age 18-90 chronic renal insufficiency stable dose of calcium-containing phosphatbinding medication for the last four weeks blood pressure=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: intake from niacin during the last six months dose-change for lipid-lowering therapy in the last six weeks another clinical trial in the last 30 days known drug use pregnancy known allergic reaction to niacin liver function disturbances lack of cooperation

Design outcomes

Primary

Measure	Time frame
Main Objective: phosphate and calcium metabolism;Secondary Objective: lipid metabolism;Primary end point(s): change in the serum phosphate level	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026